Advertisement
Journal of Investigative Dermatology Home

Golimumab for the Treatment of Hidradenitis Suppurativa in Patients with Previous TNF-α Treatment Failure

      Hidradenitis suppurativa (HS) is a chronic inflammatory disease of the skin presenting with recurrent inflammatory nodules, cysts, abscesses, sinus tracts, and scar formation. Combined medical and surgical management is often required. The only Food and Drug Administration‒approved treatment for HS, adalimumab, is a mAb targeting TNF-α (
      • Alikhan A.
      • Sayed C.
      • Alavi A.
      • Alhusayen R.
      • Brassard A.
      • Burkhart C.
      • et al.
      North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian hidradenitis suppurativa foundations: part I: diagnosis, evaluation, and the use of complementary and procedural management.
      ,
      • Alikhan A.
      • Sayed C.
      • Alavi A.
      • Alhusayen R.
      • Brassard A.
      • Burkhart C.
      • et al.
      North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian hidradenitis suppurativa foundations: part II: topical, intralesional, and systemic medical management.
      ;
      • Kimball A.B.
      • Okun M.M.
      • Williams D.A.
      • Gottlieb A.B.
      • Papp K.A.
      • Zouboulis C.C.
      • et al.
      Two phase 3 trials of adalimumab for hidradenitis suppurativa.
      ). The use of golimumab, another fully humanized TNF-α inhibitor, has been described in two cases of HS with mixed results (
      • Tursi A.
      Concomitant hidradenitis suppurativa and pyostomatitis vegetans in silent ulcerative colitis successfully treated with golimumab.
      ;
      • van der Zee H.H.
      • Prens E.P.
      Failure of anti-interleukin-1 therapy in severe hidradenitis suppurativa: a case report.
      ). Early in vivo and in vitro studies showed that golimumab has a higher affinity for transmembrane and soluble TNF-α receptors than adalimumab and infliximab, suggesting it as a potential treatment option (
      • Cunningham G.
      • Samaan M.A.
      • Irving P.M.
      Golimumab in the treatment of ulcerative colitis.
      ;
      • Flamant M.
      • Paul S.
      • Roblin X.
      Golimumab for the treatment of ulcerative colitis.
      ;
      • Shealy D.J.
      • Cai A.
      • Staquet K.
      • Baker A.
      • Lacy E.R.
      • Johns L.
      • et al.
      Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α.
      ).

      Abbreviations:

      HiSCR (Hidradenitis Suppurativa Clinical Response), HS (hidradenitis suppurativa)
      To read this article in full you will need to make a payment
      Purchase one-time access
      Society Members (SID/ESDR), remember to log in for access.
      Subscribe to Journal of Investigative Dermatology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Alikhan A.
        • Sayed C.
        • Alavi A.
        • Alhusayen R.
        • Brassard A.
        • Burkhart C.
        • et al.
        North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian hidradenitis suppurativa foundations: part I: diagnosis, evaluation, and the use of complementary and procedural management.
        J Am Acad Dermatol. 2019; 81: 76-90
        • Alikhan A.
        • Sayed C.
        • Alavi A.
        • Alhusayen R.
        • Brassard A.
        • Burkhart C.
        • et al.
        North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian hidradenitis suppurativa foundations: part II: topical, intralesional, and systemic medical management.
        J Am Acad Dermatol. 2019; 81: 91-101
        • Cunningham G.
        • Samaan M.A.
        • Irving P.M.
        Golimumab in the treatment of ulcerative colitis.
        Therap Adv Gastroenterol. 2019; 121756284818821266
        • Finlay A.Y.
        • Khan G.K.
        Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use.
        Clin Exp Dermatol. 1994; 19: 210-216
        • Flamant M.
        • Paul S.
        • Roblin X.
        Golimumab for the treatment of ulcerative colitis.
        Expert Opin Biol Ther. 2017; 17: 879-886
        • Kimball A.B.
        • Jemec G.B.
        • Yang M.
        • Kageleiry A.
        • Signorovitch J.E.
        • Okun M.M.
        • et al.
        Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment.
        Br J Dermatol. 2014; 171: 1434-1442
        • Kimball A.B.
        • Okun M.M.
        • Williams D.A.
        • Gottlieb A.B.
        • Papp K.A.
        • Zouboulis C.C.
        • et al.
        Two phase 3 trials of adalimumab for hidradenitis suppurativa.
        N Engl J Med. 2016; 375: 422-434
        • Oskardmay A.N.
        • Miles J.A.
        • Sayed C.J.
        Determining the optimal dose of infliximab for treatment of hidradenitis suppurativa.
        J Am Acad Dermatol. 2019; 81: 702-708
        • Shealy D.J.
        • Cai A.
        • Staquet K.
        • Baker A.
        • Lacy E.R.
        • Johns L.
        • et al.
        Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α.
        MAbs. 2010; 2: 428-439
        • Tursi A.
        Concomitant hidradenitis suppurativa and pyostomatitis vegetans in silent ulcerative colitis successfully treated with golimumab.
        Dig Liver Dis. 2016; 48: 1511-1512
        • van der Zee H.H.
        • Prens E.P.
        Failure of anti-interleukin-1 therapy in severe hidradenitis suppurativa: a case report.
        Dermatology. 2013; 226: 97-100
        • Zouboulis C.C.
        • Tzellos T.
        • Kyrgidis A.
        • Jemec G.B.E.
        • Bechara F.G.
        • Giamarellos-Bourboulis E.J.
        • et al.
        Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity.
        Br J Dermatol. 2017; 177: 1401-1409